OXYTOCIC PHARMACEUTICALS MARKET ANALYSIS

The global oxytocic pharmaceuticals market is estimated to be valued at US$ 128.43 million in 2023 and is expected to exhibit a CAGR of 7.8% during the forecast period (2023-2030).

Analysts’ Views on Global Oxytocic Pharmaceuticals Market:

Over the projected period, there will be an increase in the number of births that are induced and postpartum hemorrhage, which will increase the need for the use of oxytocic medications. For instance, according to Stanford Medicine Children's Health, Postpartum hemorrhage is more bleeding than normal after the birth of a baby. About 1 in 100 to 5 in 100 women have postpartum hemorrhage. It is more likely with a cesarean birth. It most often happens after the placenta is delivered, but it can also happen later.

Figure 1. Global Oxytocic Pharmaceuticals Market Share (%), by Indication, 2023

To learn more about this report, request sample copy

Global muscle stimulation devices market – Driver

Increase birthrate and higher prevalence of postpartum hemorrhage (PPH)

Increasing incidence of PPH is expected to boost growth of the global oxytocic pharmaceuticals market over the forecast period. For instance, on March 3 2023, as per the December 2021 update from United Nations International Children's Emergency Fund (UNICEF), an estimated 140 million children were born in 2021. Furthermore, as per the August 2021 update from International Institute for Sustainable Development, the global population is projected to increase to 9.7 billion by 2050. This level represents a nearly 24% increase over 2020. Because of the increased birth rate and population levels, there is a high chance for growth of the oxytocin market since oxytocin is advised for antepartum and postpartum pregnancy.

Figure 2. Global Oxytocic Pharmaceuticals Market Value (US$ Million), by Region, 2023

To learn more about this report, request sample copy

Global Oxytocic Pharmaceuticals Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global oxytocic pharmaceuticals market over the forecast period due to increasing number of preterm births, fertility rates, and increasing healthcare expenditure. North America is estimated to hold 47.5% of the market share in 2023. For instance, according to the Centers for Disease Control and Prevention (CDC), “Births: Provisional Data for 2021” report, the number of births in the United States and the general fertility rate increased for the first time in seven years in 2021. The report shows a 1% increase in births from 2020, with 3,659,289 births recorded in 2021. As per the same source, the preterm birth rate rose 4% in 2021 to 10.48%, from 10.09% in 2020.

Global Oxytocic Pharmaceuticals Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a positive impact on the global oxytocic pharmaceuticals market. For instance, in August 2021, according to an article published in the journal Morecamble Bay Medical, stated that Oxytocin also plays a protective role by increased activation of anti-apoptotic and restorative pathways. It has also been demonstrated for the cardioprotective properties and thus, the reliance of this drugs in COVID-19 increased.

Global Oxytocic Pharmaceuticals Market Segmentation:

The global oxytocic pharmaceuticals market report is segmented into Indication, Route of Administration, Source of Origin, End User and Region.

By Indication, the oxytocic pharmaceuticals market is segmented into Abortion Induced Incomplete, Inevitable Abortion, Postpartum Hemorrhage, Labor Induction, and Labor Arrest. Out of which, the Postpartum Hemorrhage (PPH) segment is expected to dominate the global oxytocic pharmaceuticals market during the forecast period and this is due to the increase in the prevalence of PPH.

By Route of Administration, the oxytocic pharmaceuticals market is segmented into Intramuscular, and Intravenous Injection/Infusion. The intravenous injection segment is expected to dominate the market over the forecast period and this is due to its rapid onset of action.

Based on Source of Origin, the oxytocic pharmaceuticals market is segmented into Synthetic Oxytocin, and Natural Oxytocin (Animal Pituitary Extract). The synthetic oxytocin segment is expected to dominate the market over the forecast period and this is created by altering the chemical structure of natural oxytocin. This alters the way the hormone works in the body. Some synthetic oxytocin derivatives are used to help pregnant women give birth, while others are used to treat conditions such as autism and schizophrenia and is expected to increase during the forecast period.

Based on End user, the oxytocic pharmaceuticals market is segmented into Hospitals, and Maternity Clinics. The hospitals segment is expected to dominate the market over the forecast period and this is attributed to the increasing prevalence of postpartum hemorrhage and increase in abortion.

Among all segmentation, the Indication segment has the highest potential due to the increasing prevalence of Labor Induction over the forecast period. For instance, in January 2022, according to an article published in the journal PLoS one, the Post-term pregnancy was the most common indication for induction of labor101 (35.6%), followed by PROM 71(25%), and hypertensive disorders 58 (20.4%). The overall prevalence of failed induction was observed to be 63 (22.2%).

Global Oxytocic Pharmaceuticals Market Cross Sectional Analysis:

Rising incidence of adolescent pregnancies in Latin America and the Caribbean (LAC) is also expected to boost demand for oxytocic pharmaceuticals in Latin America region and Caribbean. For instance, in August 2020, according to the Pan American Health Organization (PAHO), the adolescent birth rate (ABR) in LAC fell from 65.6 (2010–2015) to 60.7 (2015–2020), representing a 7.47% decrease in the ABR. However, wide variations persist between sub regions and countries, and within countries. The estimated number of unsafe abortions in girls aged 15-19 years in LAC in 2019 was 876,000.

Global Oxytocic Pharmaceuticals Market: Key Developments

On May 22 2023, Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced that it has entered into a research collaboration agreement to evaluate the effect of TNX-1900 (intranasal potentiated oxytocin) on capsaicin- or electrical stimulation-induced forehead dermal blood flow in healthy female human volunteers.

On May 15 2023, Monash University is collaborating with Iconovo AB, a Research & Development company that develops and commercializes adjuvants and vaccine to develop an inhalable, preventive oxytocin treatment that aims to provide effective protection against these bleedings. Iconovo AB announced that Monash has started a clinical phase I study with the treatment in Melbourne. In addition, the product is featured in Designing Motherhood, an international design exhibition. Måns Österberg at Iconovo tells us more about the project.

In May 2022, the Central government of India allowed the import of oxytocin reference standards for testing and analysis after submitting a test license issued by the Drugs Controller General of India (DCGI).

Global Oxytocic Pharmaceuticals Market: Key Trends

Market players require WHO prequalification for the products that are to be supplied to the international organizations. Manufacturers who adhere to the WHO’s prequalification may have greater possibility to gain larger market share than the non-prequalified manufacturers.

Increasing adolescent pregnancies in Latin America is expected to lead to high demand for oxytocics for labor or abortion in the region.  For instance, on June 2, 2023, according to the WHO, as of 2019, adolescents aged 15–19 years in low-and middle-income countries (LMICs) had an estimated 21 million pregnancies each year, of which approximately 50% were unintended and which resulted in an estimated 12 million births. Adolescent mothers (aged 10–19 years) face higher risks of eclampsia, puerperal endometritis and systemic infections than women aged 20–24 years, and babies of adolescent mothers face higher risks of low birth weight, preterm birth and severe neonatal condition.

Global Oxytocic Pharmaceuticals Market: Restraint

Problems with oxytocin preparations quality

Injectable oxytocin, given intravenously or intramuscularly, is recommended by the World Health Organization (WHO) as the first-line medicine for the prevention and treatment of postpartum haemorrhage. It is additionally used for the induction and augmentation of labour. Primary causes for substandard oxytocin quality are considered to be poor-quality manufacturing and/or product degradation in the supply chain. For instance, according to WHO (World Health Organization), 2021 report of Regulatory guidance for assessment and management of applications for marketing authorization of oxytocin, suggested the precautionary measures to be taken related to the supply chain, manufacturing  and product degradation of Oxytocic pharmaceuticals. The causes of the issue with oxytocin preparations were also noted by the WHO.

Global Oxytocic Pharmaceuticals Market - Key Players

Major players operating in the global oxytocic pharmaceuticals market include Major players operating in the global oxytocic pharmaceuticals market include Fresenius Kabi AG, Biofutura SpA, Baxter Healthcare Corporation, Pfizer, Inc., Ferring B.V., Novartis AG, Teva Pharmaceuticals Industries Ltd., Abbott Laboratories, AdvaCare Pharma, and EVER Pharma.

Definition: Oxytocic Drugs are drugs that stimulates contraction of the myometrium. Oxytocics are used to induce labor, obstetric at term, to prevent or control postpartum or postabortion haemorrhage, and to assess foetal status in high risk pregnancies. They may also be used alone or with other drugs to induce abortions (abortifacients). Oxytocin injection is used to begin or improve contractions during labor. Oxytocin also is used to reduce bleeding after childbirth. It also may be used along with other medications or procedures to end a pregnancy. Oxytocin is in a class of medications called oxytocic hormones. It works by stimulating uterine contractions. It is injected into a muscle, or given as an infusion into a vein. Natural oxytocin is prepared by extracting from the pituitary glands of the animals.